Tests whether ulcerative colitis treatment can be reduced after healing
Compares stopping or lowering medicine with continuing it in ulcerative colitis patients.
Plain-language title generated from the registry record
Registry title: STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
Key facts
- Where
- Chicago, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with ulcerative colitis who have been in deep remission, with no sign of inflammation, for at least 12 months. It tests whether lowering or stopping treatment keeps the remission going.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Ulcerative colitis diagnosed at least 3 years ago, in deep remission: no signs of active inflammation on endoscopy and biopsies within the last 12 months, and in clinical, biochemical, radiologic and endoscopic remission since the last colonoscopy (fecal calprotectin <100).
- Earlier treatment
- No change in treatment and no corticosteroid use after the colonoscopy that showed histological normalization or quiescence.
- Biomarker or test result
- Fecal calprotectin <100. A persistently normal calprotectin test can count instead of a yearly colonoscopy if the last colonoscopy was within 3 years and showed normal findings.
Main reasons for not taking part
- Any active inflammation (clinical, ultrasound, blood or stool test, or endoscopy)
- Any change in treatment after the colonoscopy showing remission
- Corticosteroid use after that colonoscopy
- History of primary sclerosing cholangitis, or high-grade dysplasia that is invisible or not removed
- Pregnancy or actively trying to conceive
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06693310, who can take part
Where in United States
- University of ChicagoChicago, United StatesContact: David T Rubin, MD (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Chicago
- Trial code
- NCT06693310
- Record updated
- 19 October 2026
- Original description
The goal of this study is to better understand treatment strategies for people with ulcerative colitis (UC). Researchers will compare patients with UC in histologic remission (no evidence of inflammation or active disease on endoscopy and biopsies) who continue to take medical therapy to patients with UC who de-escalate (decrease or discontinue) medical therapy. Both treatment strategies are considered within regular medical practice. Researchers want to find out whether remission can be maintained after de-escalation of therapy.Read full original descriptionShow less
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
The goal of this study is to better understand treatment strategies for people with ulcerative colitis (UC). Researchers will compare patients with UC in histologic remission (no evidence of inflammation or active disease on endoscopy and biopsies) who continue to take medical therapy to patients with UC who de-escalate (decrease or discontinue) medical therapy. Both treatment strategies are considered within regular medical practice. Researchers want to find out whether remission can be maintained after de-escalation of therapy.
Participants will be:
* either be randomly assigned to continue medical therapy or de-escalate medical therapy -OR- be assigned per the participant's preference * clinically managed according to regular medical care * asked to provide blood, stool (poop), and tissue samples for study purposes
Inclusion: Consenting patients aged 18 to 75 years with an established diagnosis of ulcerative colitis (UC) for at least 3 years; Patients in deep remission, defined by the absence of endoscopic and histologic signs of active inflammation (i.e. histological normalization or histological quiescence) in all biopsies obtained during colonoscopy, within the last 12 months; If the most recent colonoscopy is within the last 3 years and demonstrates normalized/quiescent pathology findings (i.e., patient is in stable remission), the patient would not be expected to undergo yearly colonoscopies. Therefore, a persistent normalized calprotectin test will be accepted as sufficient to define deep remission with no change in therapy; Patients in clinical, biochemical (fecal calprotectin <100), radiologic and endoscopic remission since the last colonoscopy.
Exclusion: Patients with any changes in therapy after colonoscopy showing histological normalization or quiescence; Corticosteroid use after colonoscopy showing histologic normalization or quiescence; Patients with any noted history of primary sclerosing cholangitis or invisible or unresected high-grade dysplasia (suspected or confirmed); Any noted active inflammation [clinical, sonographic, biochemical, endoscopic (in any colonic segment)]; Pregnancy or actively trying to conceive; Inability to follow the proposed sample collection and monitoring protocol.